Advanced Biomed Operating Income Over Time
| ADVB Stock | 0.24 0 0.58% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Advanced Biomed Performance and Advanced Biomed Correlation. Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Advanced Biomed. If investors know Advanced will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Advanced Biomed assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Advanced Biomed Common requires distinguishing between market price and book value, where the latter reflects Advanced's accounting equity. The concept of intrinsic value - what Advanced Biomed's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Advanced Biomed's price substantially above or below its fundamental value.
Understanding that Advanced Biomed's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Advanced Biomed represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Advanced Biomed's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Advanced Biomed Common and related stocks such as BioNexus Gene Lab, Trinity Biotech plc, and Ridgetech Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BGLC | (840) | (840) | (840) | (840) | (840) | (840) | (840) | (127.9 K) | 59.9 K | (275.7 K) | 1.3 M | 1.1 M | (291.2 K) | (2.6 M) | (1.6 M) | (1.4 M) | (1.3 M) |
| TRIB | (4.2 M) | 15.8 M | 17.2 M | 17.9 M | 18 M | 13.4 M | 7.5 M | 5.5 M | 3.3 M | 872 K | 82 K | 3.9 M | (15.3 M) | (27 M) | (21.2 M) | (19 M) | (18.1 M) |
| RDGT | (3.7 K) | 10.5 M | (12.6 M) | (19.2 M) | 1.7 M | (24.8 K) | (6.1 M) | (18 M) | (876.1 K) | (7 M) | (8.8 M) | (2.7 M) | (20.9 M) | (3.5 M) | (1 M) | (931.8 K) | (978.4 K) |
| APM | (878.2 K) | (878.2 K) | (878.2 K) | (878.2 K) | (878.2 K) | (878.2 K) | (878.2 K) | (5.7 M) | (10.3 M) | (18.2 M) | (19.9 M) | (19.2 M) | (17.5 M) | (10.6 M) | (3.8 M) | (3.4 M) | (3.6 M) |
| XAIR | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (2.2 M) | (2.2 M) | (29.3 K) | (11.1 M) | (3.1 M) | (18.1 M) | (22.2 M) | (40.7 M) | (52.1 M) | (63 M) | (44.5 M) | (40.1 M) | (38.1 M) |
| MRKR | (1.1 M) | (2.6 M) | (6.2 M) | (2.7 M) | (3.4 M) | (6.2 M) | (8.5 M) | (11.5 M) | (148.2 M) | (22.5 M) | (28.9 M) | (39.5 M) | (19.8 M) | (14.6 M) | (11.1 M) | (10 M) | (10.5 M) |
| MBIO | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | 11.4 M | (31.8 M) | (31.2 M) | (45.9 M) | (56.8 M) | (66.7 M) | (76.2 M) | (50.7 M) | (16.2 M) | (14.6 M) | (15.4 M) |
| TNON | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (536.3 K) | (6.5 M) | (18.7 M) | (15.7 M) | (13.8 M) | (12.4 M) | (13 M) |
| GELS | (647.6 K) | (647.6 K) | (647.6 K) | (647.6 K) | (647.6 K) | (647.6 K) | (647.6 K) | (647.6 K) | (647.6 K) | (647.6 K) | (647.6 K) | (3.2 M) | (3.1 M) | (2.9 M) | (5.5 M) | (4.9 M) | (4.7 M) |
Advanced Biomed Common and related stocks such as BioNexus Gene Lab, Trinity Biotech plc, and Ridgetech Operating Income description
Operating Income is the amount of profit realized from Advanced Biomed Common operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Advanced Biomed Common is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Advanced Biomed Common | ADVB |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 122 East 42nd |
| Exchange | NASDAQ Exchange |
null 0.2386
Check out Advanced Biomed Performance and Advanced Biomed Correlation. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Advanced Biomed technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.